**Product Name:** Mavoglurant  
**Cat. No.:** HY-15257  
**CAS No.:** 543906-09-8  
**Molecular Formula:** C_{19}H_{23}NO_{3}  
**Molecular Weight:** 313.39  
**Target:** mGluR  
**Pathway:** GPCR/G Protein  
**Solubility:** DMSO: ≥ 47 mg/mL

**BIOLOGICAL ACTIVITY:**

Mavoglurant is a structurally novel, non-competitive mGlu5 receptor antagonist, has an IC50 of 30 nM in a functional assay with human mGluR5.  
**IC50 value:** 30 nM  
**Target:** mGluR5  
**in vitro:** Mavoglurant is a selective non-competitive antagonist which showed efficacy in the treatment of L-dopa induced dyskinesias in Parkinson’s disease and Fragile X mental retardation in proof of principle studies. Mavoglurant is selective over the other mGluR subtypes, iGluRs and a panel of 238 CNS relevant receptors, transporter or enzymes. [1]  
**In vivo:** Mavoglurant shows an improved pharmacokinetic profile in rat and efficacy in the stress-induced hyperthermia test in mice as compared to the prototypic mGluR5 antagonist MPEP.[1]

**PROTOCOL (Extracted from published papers and Only for reference)**

Animal administration [1] Male OF1/IC mice were housed in groups of twelve, in macrolon cages in the experimental room of the laboratory, which was temperature controlled and equipped with artificial illumination. Animals had always free access to food and water. AFQ056 was administered to mice orally as a suspension in 0.5% methylcellulose (volume 2 ml/kg) at the doses of 0.1/1/10 mg/kg.

**References:**


---

**Caution:** Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898   Fax: 609-228-5909   E-mail: tech@MedChemExpress.com  
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA